Skip to main content

Advertisement

SpringerLink
Log in

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Objective The mammalian target of rapamycin (mTOR) pathway, an important regulator of multiple cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis, is up-regulated in many cancers. It has achieved considerable importance. This study was conducted to determine the status of the mTOR pathway in human hepatocellular carcinoma (HCC) and to investigate its relationship with the prognosis of HCC. Methods PTEN, pAkt, p27, and pS6 expression in cryo-sections gathered from 528 cases with HCC by the method of immunohistochemistry. Kaplan–Meier survival and Cox regression analyses were performed to evaluate the prognosis of HCC. Results The mTOR pathway was more significantly altered in high-grade tumors, and tumors with poor prognostic features. Especially, pAkt and cytoplasmic p27 expression showed the strongest associations with pathological parameters of HCC. Statistical analysis showed that HCC patients expressing pAkt, PTEN, cytoplasmic p27, and pS6 have different overall survival rates relative to those not expressing these proteins. Cox multi-factor analysis showed that tumor differentiation (P = 0.006), vascular invasion (P = 0.028), TNM stage (P = 0.005), pAkt (P = 0.021), PTEN (P = 0.003), p27 (P = 0.018) and pS6 (P = 0.002) were independent prognosis factors for HCC. Conclusion: Expression of the mTOR pathway components, which are related with the transferability and invasive capacity of HCC cells, may be used as prognostic indicators in HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

mTOR:

Mammalian target of rapamycin

HCC:

Hepatocellular carcinoma

References

  1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87. doi:10.1038/nrc1934.

    Article  CAS  PubMed  Google Scholar 

  2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46. doi:10.1038/ng0802-339.

    Article  CAS  PubMed  Google Scholar 

  3. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107–16. doi:10.1038/nrc1799.

    Article  CAS  PubMed  Google Scholar 

  4. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24. doi:10.1038/ng1494.

    Article  CAS  PubMed  Google Scholar 

  5. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353–61. doi:10.1016/j.molmed.2005.06.007.

    Article  CAS  PubMed  Google Scholar 

  6. Hardie DG. The AMP-activated protein kinase pathway new players upstream and downstream. J Cell Sci. 2004;117:5479–87. doi:10.1242/jcs.01540.

    Article  CAS  PubMed  Google Scholar 

  7. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol. 2005;17:158–66. doi:10.1016/j.ceb.2005.02.008.

    Article  CAS  PubMed  Google Scholar 

  8. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60. doi:10.1016/j.critrevonc.2004.09.009.

    Article  PubMed  Google Scholar 

  9. Shaw RJ, Bardeesy N, Manning BD. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6(1):91–9. doi:10.1016/j.ccr.2004.06.007.

    Article  CAS  PubMed  Google Scholar 

  10. Chan S. Targeting the mTOR: a new approach to treating cancer. Br J Cancer. 2004;91:1420–4. doi:10.1038/sj.bjc.6602162.

    Article  CAS  PubMed  Google Scholar 

  11. Ishak KG, Anthony PP, Sobin LH. Nonepithelial tumors. In: Ishak KG, editor. Histological typing of tumors of the liver. World Health Organization International Classification of Tumors. Berlin: Springer; 1994. pp. 22–7.

  12. Wittekind C. Pitfalls in the classification of liver tumors. Pathologe. 2006;27:289–93. doi:10.1007/s00292-006-0834-1.

    Article  CAS  PubMed  Google Scholar 

  13. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–93. doi:10.1200/JCO.2006.09.4565.

    Article  PubMed  Google Scholar 

  14. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–16. doi:10.1200/JCO.2007.15.6521.

    Article  PubMed  Google Scholar 

  15. Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67. doi:10.1002/cncr.22677.

    Article  CAS  PubMed  Google Scholar 

  16. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. doi:10.1053/j.gastro.2007.04.061.

    Article  CAS  PubMed  Google Scholar 

  17. Blum H. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391–400.

    CAS  PubMed  Google Scholar 

  18. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323–33. doi:10.1093/aje/155.4.323.

    Article  CAS  PubMed  Google Scholar 

  19. Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. Alcohol Clin Exp Res. 2004;28:164S–8S.

    PubMed  Google Scholar 

  20. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H. JACC Study Group. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer. 2005;93:607–10. doi:10.1038/sj.bjc.6602737.

    Article  CAS  PubMed  Google Scholar 

  21. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506–13. doi:10.1016/j.jhep.2007.03.015.

    Article  CAS  PubMed  Google Scholar 

  22. Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008; 2047–63.

  23. Zhou X, Tan M, Stone Hawthorne V. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 over expression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10:6779–88. doi:10.1158/1078-0432.CCR-04-0112.

    Article  CAS  PubMed  Google Scholar 

  24. Luo J, Manning BD, Cantley LC. Targeting the PI3 K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62. doi:10.1016/S1535-6108(03)00248-4.

    Article  CAS  PubMed  Google Scholar 

  25. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–48. doi:10.1038/nrc1362.

    Article  CAS  PubMed  Google Scholar 

  26. Pene F, Claessens Y-E, Muller O. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21:6587–97. doi:10.1038/sj.onc.1205923.

    Article  CAS  PubMed  Google Scholar 

  27. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45. doi:10.1101/gad.1212704.

    Article  CAS  PubMed  Google Scholar 

  28. Neshat MS, Mellinghoff IK, Tran C. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314–9. doi:10.1073/pnas.171076798.

    Article  CAS  PubMed  Google Scholar 

  29. Wu FY, Wang SE, Sanders ME. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 2006;66:2162–72. doi:10.1158/0008-5472.CAN-05-3304.

    Article  CAS  PubMed  Google Scholar 

  30. Viglietto G, Motti ML, Bruni P. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136–44. doi:10.1038/nm762.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Surgery Department of XiangYa Hosptial, Central South University, Changsha, Hunan, 410078, China

    Ledu Zhou, Yun Huang, Jingdong Li & Zhiming Wang

Authors
  1. Ledu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingdong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhiming Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhiming Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, L., Huang, Y., Li, J. et al. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27, 255–261 (2010). https://doi.org/10.1007/s12032-009-9201-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9201-4

Keywords

Search

Navigation